Melanotan II — 10mg | Research Use Only (RUO)

$47.99

Melanotan II (10mg) lyophilized powder. Synthetic cyclic melanocortin peptide for laboratory research applications. Purity ≥98%. Certificate of Analysis available.

6 in stock

SKU: RES-MT2-10 Category:

Description

A synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone currently being investigated in controlled laboratory environments for its non-selective interaction with multiple melanocortin receptor subtypes.

For laboratory research use only. Not for human or animal consumption.

OVERVIEW

Melanotan II is a cyclic lactam analog of alpha-MSH studied in preclinical models for its non-selective binding across multiple melanocortin receptor subtypes including MC1R, MC3R, MC4R, and MC5R. Laboratory research has examined its broad receptor affinity profile, comparative selectivity against linear analogs, and downstream signaling characteristics under controlled experimental conditions.

Supplied as a lyophilized powder for analytical and experimental research applications.

PRODUCT SPECIFICATIONS

Compound: Melanotan II (Cyclic Alpha-MSH Analog)
Quantity: 10 mg per vial
Form: Lyophilized powder
Purity: ≥98%
Storage: -20°C recommended, protect from light
CAS: 121062-08-6

RESEARCH APPLICATIONS

– Non-selective melanocortin receptor binding studies
– Multi-receptor subtype signaling analysis
– Cyclic vs. linear peptide structure-function research
– MC1R/MC3R/MC4R/MC5R comparative modeling

RESEARCH USE ONLY

This product is intended strictly for laboratory research purposes. Not for human consumption. Not for veterinary use. Not for therapeutic or diagnostic applications. Not intended to treat, cure, or prevent any condition. Use is limited to qualified professionals in controlled laboratory environments.

Certificate of Analysis available upon request.

Additional information

Weight 0.1 lbs
size

30mg

Reviews

There are no reviews yet.

Be the first to review “Melanotan II — 10mg | Research Use Only (RUO)”

Your email address will not be published. Required fields are marked *